

## RHABDOMYOLYSIS PROTOCOL FOR A&amp;E (New patient)

Priority patient: must not be kept waiting in A&amp;E

## 1 DEFINITION AND SYMPTOMS

Rhabdomyolysis (RM) is the sudden destruction of skeletal muscle fibres, characterised by an increase in CPK levels at the time the acute attack occurs. It can be associated with acute cardiac damage. The presence of myoglobinuria indicates an increase in CPK level to > 20 000 IU/L (N <250 U/L) and hence severe rhabdomyolysis.

The clinical signs of rhabdomyolysis include:

- Classically, myalgia = muscle pain (which may precede CPK elevation), muscle fatigue
- Sometimes, diffuse poorly-defined pain (in the back or neck), or inability to walk / stand, exhaustion.
- Cardiac rhythm disorders, heart failure
- Impaired consciousness
- Hypovolaemic shock
- Myoglobinuria (sign of severe rhabdomyolysis)

Differential diagnosis Guillain-Barré syndrome (pain in the legs), myelitis, transient synovitis of the hip, myasthenia (muscle fatigue), acute hepatitis, hepatocellular injury



## 2 TREATMENT TO BE STARTED URGENTLY

**Acute rhabdomyolysis with CPK > 5000 U/L is always an emergency situation, because it is impossible to predict how severe the attack will become in the following hours.**

- If signs of hypo-perfusion, rehydrate with Ringer Lactate or NaCl 0.9% at 10ml/kg (maximum 500 ml) if no cardiac signs; reassess and continue if necessary.
- Start specific treatment for any intercurrent infection.
- If CPK <20 000 U/L: Infusion for IV fluid therapy
  - G10% (10% glucose) + NaCl 6g/L WITHOUT POTASSIUM. Intake 2L/m<sup>2</sup>/day (maximum flow rate 150 ml/hr). Do not use ready-made solutions containing potassium (polyionic, Glucidion, Bionolyte etc.) [body surface area = (4W+7)/(W+90)]
- If CPK >20 000 U/L or immediately if myoglobinuria: arrange transfer to HDU/ICU and, as soon as possible, start hyperhydration, after getting agreement from intensive care doctor: Volume 3L/m<sup>2</sup>/day (maximum flow rate 150 ml/hr)
  - Preparation for 1 litre of fluid: 200 ml of G30% (30% glucose) + 400 ml of Bicarbonate 14 ‰ + 400 ml of NaCl 0.9% No potassium or calcium
  - Provided that there is no infection, and after obtaining the opinion of a specialist in metabolic disease, neurology or internal medicine, consider a short period of corticosteroid therapy before transfer to HDU/ICU (rationale: inflammatory component of RM. Will be useful if there is a LPIN1 mutation) Methylprednisolone 1 to 2mg/kg/day for 3 to 5 days.
- Potential specific treatments:
  - Levocarnil 20-50 mg/kg/day by continuous IV, not exceeding 6g/24 hrs for adults; if there is suspected fatty acid oxidation or carnitine transporter deficiency (see over - In this case, the intake of glucose must be reassessed - see protocol for fatty acid oxidation deficiency - G2M web site). Contraindicated if there is cardiac rhythm disorder or suspicion of TANGO2 deficiency.
  - Consider Dantrolene IV if RYR1 mutation is suspected (see over).
  - If there are underlying neurological abnormalities, known hypothyroidism or long QT, TANGO2 deficiency should be suspected (see drug contraindications in the specific emergency protocol)

## 3 SIGNS OF SEVERITY = seek advice / transfer to ICU

- CPK > 20 000 IU/L (change infusion as indicated above only if transfer to HDU/ITU: Volume 3L/m<sup>2</sup>/day (maximum flow rate 150 ml/hr)
  - Consider extra-renal purification if potassium level > 5mmol/L despite correctly performed hyperhydration, if there is any ECG abnormality, if anuria/oliguria with serum electrolyte results contraindicating continuation of hyperhydration, or if there is kidney injury (creatinine levels do not reflect the severity of kidney injury, because it is released following muscle necrosis; urea is more reliable).
  - Monitoring in ICU: blood glucose, Na and K every 2 hours during the first 24 hours, complete electrolyte panel with Ca, P, Mg, urea, creatinine, CPK every 6 hrs. Hourly monitoring of urine output > 2ml/kg/hr, urine pH and density < 1005. Blood electrolytes every 3 hrs to adjust hyperhydration. ECG in place, trace per hour. Echocardiogram.
- Cardiac rhythm disorders, ECG signs of hyperkalaemia, hyperkalaemia > 7 mmol/L
- Oliguria / anuria, port wine-coloured urine, kidney failure
- Neurological disorders, exhaustion (risk of hyperosmolar coma)

## 4 MONITORING (except for severe rhabdomyolysis CPK &gt; 20 000 U/L in ICU)

- CPK, electrolytes, Ca, P, urine output and colour 4 hrs later, then every 4 hrs to 8 hrs depending on the subsequent course of CPK levels. Adjust potassium intake according to potassium level and renal function (if there is no potassium in the infusion, there is also a risk of hypokalaemia). Continuous cardiac monitoring, ECG at 4 hrs, then once a day; Monitoring of cardiac function (clinical and ultrasound).

## 5

## AETIOLOGY

Acute rhabdomyolysis can be triggered by a viral cause (particularly influenza virus, Covid-19), a fever, fasting, anaesthesia, and physical effort. The challenge is to recognise an underlying genetic cause, which could account for recurrent attacks. The search for an aetiology can be guided by the patient's history: acute or chronic nature of the myolysis (return of CPK levels to normal or persistence of elevated CPK some time after the acute episode), severity of the acute episode (very severe if CPK > 50 000 U/L), age of onset, associated signs (neurological, muscular, cardiac etc.). Non-exhaustive list

- **The causes of acute rhabdomyolysis** (with subsequent normalisation of CPK levels) **include:**
  - **Endocrine causes: cortisol deficiency, hypothyroidism.**
  - **Inflammatory myositis / dermatomyositis:** inflammatory syndrome (+/-), skin rashes, joint involvement, sometimes with no functional deficits, painless. Check that there is no inflammatory syndrome. **Specific therapeutic emergency: seek specialist opinion.**
  - **Toxic or traumatic causes.**
  - **Fatty acid oxidation disorder:** episode can be associated with hypoketotic hypoglycaemia, hyperammonaemia, liver damage, Reye syndrome, myocardial damage / rhythm disorder.
  - **LPIN1 deficiency:** acute rhabdomyolysis which is often very severe, with early onset (under 6 years of age). Sometimes chronic moderate elevation of CPK with muscle fatigue (see specific emergency protocol).
  - **Calcium channel abnormalities (including mutation of RYR1 and related genes):** most often triggered by anaesthesia or physical exercise, associated with malignant hyperthermia, dominant transmission (look for family history of rhabdomyolysis or anaesthetic incidents) (see specific emergency protocol).
  - **TANGO2 mutations:** associated neurological signs (mental retardation, dystonia, encephalopathy, epilepsy) and/or non-neurological signs (cardiac signs e.g. long QT / Brugada syndrome / ventricular rhythm disorders; hypothyroidism). Numerous anaesthetic agents contraindicated (see specific emergency protocol).
- **Among the causes of chronic rhabdomyolysis** (no subsequent return of CPK levels to normal):
  - **Myopathies and muscular dystrophies:** clinically, look for proximal muscle weakness, calf hypertrophy and sometimes cognitive abnormalities.
  - **Some types of glycogen storage disease:** which can be accompanied by liver damage with hypoglycaemia (Glycogen storage diseases type III, VI, IX), or muscle involvement alone (glycogen storage disease type II (Pompe disease), type V (McArdle disease), type VII (phosphoglycerate kinase deficiency), type VIII (phosphoglycerate mutase deficiency), type IX (phosphoglycerate kinase 2 deficiency), type X (phosphoglycerate kinase 1 deficiency), type XI (phosphoglycerate kinase 3 deficiency), type XII (phosphoglycerate kinase 4 deficiency), type XIII (phosphoglycerate kinase 5 deficiency), type XIV (phosphoglycerate kinase 6 deficiency), type XV (phosphoglycerate kinase 7 deficiency), type XVI (phosphoglycerate kinase 8 deficiency), type XVII (phosphoglycerate kinase 9 deficiency), type XVIII (phosphoglycerate kinase 10 deficiency), type XIX (phosphoglycerate kinase 11 deficiency), type XX (phosphoglycerate kinase 12 deficiency), type XXI (phosphoglycerate kinase 13 deficiency), type XXII (phosphoglycerate kinase 14 deficiency), type XXIII (phosphoglycerate kinase 15 deficiency), type XXIV (phosphoglycerate kinase 16 deficiency), type XXV (phosphoglycerate kinase 17 deficiency), type XXVI (phosphoglycerate kinase 18 deficiency), type XXVII (phosphoglycerate kinase 19 deficiency), type XXVIII (phosphoglycerate kinase 20 deficiency), type XXIX (phosphoglycerate kinase 21 deficiency), type XXX (phosphoglycerate kinase 22 deficiency), type XXXI (phosphoglycerate kinase 23 deficiency), type XXXII (phosphoglycerate kinase 24 deficiency), type XXXIII (phosphoglycerate kinase 25 deficiency), type XXXIV (phosphoglycerate kinase 26 deficiency), type XXXV (phosphoglycerate kinase 27 deficiency), type XXXVI (phosphoglycerate kinase 28 deficiency), type XXXVII (phosphoglycerate kinase 29 deficiency), type XXXVIII (phosphoglycerate kinase 30 deficiency), type XXXIX (phosphoglycerate kinase 31 deficiency), type XXXX (phosphoglycerate kinase 32 deficiency), type XXXXI (phosphoglycerate kinase 33 deficiency), type XXXXII (phosphoglycerate kinase 34 deficiency), type XXXXIII (phosphoglycerate kinase 35 deficiency), type XXXXIV (phosphoglycerate kinase 36 deficiency), type XXXXV (phosphoglycerate kinase 37 deficiency), type XXXXVI (phosphoglycerate kinase 38 deficiency), type XXXXVII (phosphoglycerate kinase 39 deficiency), type XXXXVIII (phosphoglycerate kinase 40 deficiency), type XXXXIX (phosphoglycerate kinase 41 deficiency), type XXXXX (phosphoglycerate kinase 42 deficiency), type XXXXXI (phosphoglycerate kinase 43 deficiency), type XXXXXII (phosphoglycerate kinase 44 deficiency), type XXXXXIII (phosphoglycerate kinase 45 deficiency), type XXXXXIV (phosphoglycerate kinase 46 deficiency), type XXXXXV (phosphoglycerate kinase 47 deficiency), type XXXXXVI (phosphoglycerate kinase 48 deficiency), type XXXXXVII (phosphoglycerate kinase 49 deficiency), type XXXXXVIII (phosphoglycerate kinase 50 deficiency), type XXXXXIX (phosphoglycerate kinase 51 deficiency), type XXXXXX (phosphoglycerate kinase 52 deficiency), type XXXXXXI (phosphoglycerate kinase 53 deficiency), type XXXXXXII (phosphoglycerate kinase 54 deficiency), type XXXXXXIII (phosphoglycerate kinase 55 deficiency), type XXXXXXIV (phosphoglycerate kinase 56 deficiency), type XXXXXXV (phosphoglycerate kinase 57 deficiency), type XXXXXXVI (phosphoglycerate kinase 58 deficiency), type XXXXXXVII (phosphoglycerate kinase 59 deficiency), type XXXXXXVIII (phosphoglycerate kinase 60 deficiency), type XXXXXXIX (phosphoglycerate kinase 61 deficiency), type XXXXXXX (phosphoglycerate kinase 62 deficiency), type XXXXXXXI (phosphoglycerate kinase 63 deficiency), type XXXXXXXII (phosphoglycerate kinase 64 deficiency), type XXXXXXXIII (phosphoglycerate kinase 65 deficiency), type XXXXXXXIV (phosphoglycerate kinase 66 deficiency), type XXXXXXXV (phosphoglycerate kinase 67 deficiency), type XXXXXXXVI (phosphoglycerate kinase 68 deficiency), type XXXXXXXVII (phosphoglycerate kinase 69 deficiency), type XXXXXXXVIII (phosphoglycerate kinase 70 deficiency), type XXXXXXXIX (phosphoglycerate kinase 71 deficiency), type XXXXXXXX (phosphoglycerate kinase 72 deficiency), type XXXXXXXXI (phosphoglycerate kinase 73 deficiency), type XXXXXXXXII (phosphoglycerate kinase 74 deficiency), type XXXXXXXXIII (phosphoglycerate kinase 75 deficiency), type XXXXXXXXIV (phosphoglycerate kinase 76 deficiency), type XXXXXXXXV (phosphoglycerate kinase 77 deficiency), type XXXXXXXXVI (phosphoglycerate kinase 78 deficiency), type XXXXXXXXVII (phosphoglycerate kinase 79 deficiency), type XXXXXXXXVIII (phosphoglycerate kinase 80 deficiency), type XXXXXXXXIX (phosphoglycerate kinase 81 deficiency), type XXXXXXXXX (phosphoglycerate kinase 82 deficiency), type XXXXXXXXXI (phosphoglycerate kinase 83 deficiency), type XXXXXXXXXII (phosphoglycerate kinase 84 deficiency), type XXXXXXXXXIII (phosphoglycerate kinase 85 deficiency), type XXXXXXXXXIV (phosphoglycerate kinase 86 deficiency), type XXXXXXXXXV (phosphoglycerate kinase 87 deficiency), type XXXXXXXXXVI (phosphoglycerate kinase 88 deficiency), type XXXXXXXXXVII (phosphoglycerate kinase 89 deficiency), type XXXXXXXXXVIII (phosphoglycerate kinase 90 deficiency), type XXXXXXXXXIX (phosphoglycerate kinase 91 deficiency), type XXXXXXXXXX (phosphoglycerate kinase 92 deficiency), type XXXXXXXXXXI (phosphoglycerate kinase 93 deficiency), type XXXXXXXXXXII (phosphoglycerate kinase 94 deficiency), type XXXXXXXXXXIII (phosphoglycerate kinase 95 deficiency), type XXXXXXXXXXIV (phosphoglycerate kinase 96 deficiency), type XXXXXXXXXXV (phosphoglycerate kinase 97 deficiency), type XXXXXXXXXXVI (phosphoglycerate kinase 98 deficiency), type XXXXXXXXXXVII (phosphoglycerate kinase 99 deficiency), type XXXXXXXXXXVIII (phosphoglycerate kinase 100 deficiency).

## 6 TESTS TO DETERMINE AETIOLOGY

**Tests to be performed in all cases of acute rhabdomyolysis when starting treatment in A&E:**

- Blood gases, electrolytes, venous blood lactate, calcium, phosphate, urine dipstick and electrolytes.
- Liver function tests (AST, ALT, GGT, ALP, Bilirubin), PT, factor V, blood ammonia, glucose.
- Inflammation panel (CRP, FBC) with additional tests following specialist advice if suspicion of myositis or dermatomyositis.
- Cortisol. Thyroid function tests
- Acylcarnitine profile: 1 green heparin tube
- Urinary organic acid chromatography: collect the first urine samples after the episode, minimum 2 mL of urine to freeze
- Cardiology investigations: ECG, echocardiogram

**Give the patient a prescription for follow-up check of CPK some time after the episode.** Complete the 8 hr cortisol test, thyroid function tests and echocardiogram if not already done.

**Refer the patient to inherited metabolic disease specialists at the Necker hospital** who will oversee the subsequent **metabolic and/or neuromuscular investigations**, in collaboration with **doctors at the neuromuscular reference centre**, for example:

- If CPK level returns to normal: metabolic panel: blood uric acid level, redox state, consider tests for genes specific to metabolism and calcium
- If chronic myolysis: neuromuscular specialist opinion, consider autoantibodies specific to dermatomyositis / necrotising myopathy: 1 dry red tube (6mL) with no anti-coagulant (for example at the Pitié-Salpêtrière hospital), acid maltase activity, muscle glycogen storage diseases (metabolic panel) and myopathies/dystrophies/myotonia: ENMG +/- muscle biopsy, neuromuscular panel. Consider rarer causes: PGM1-CDG, mitochondrial respiratory chain disorders etc.

**If death occurs:** - 5 mL blood in EDTA tube at ambient temperature for gene panels.

- Skin biopsy for fibroblast culture (kept in culture medium or sterile physiological saline at ambient temperature).
- Muscle biopsy for histology and western blot (fresh muscle in physiological saline at ambient temperature), myoblasts (as for fibroblasts - biobank laboratory) and frozen muscle sample (liquid nitrogen). Enquiries relating to dispatch of samples to be made during working hours.

## NUMBERS AND MEDICAL SPECIALISTS

On-call telephone numbers for metabolic emergencies:

At night, only medical teams can call in emergency situations, and only if the emergency certificate has not been understood or if the clinical state or test results are worrying. As far as possible, make calls before nighttime.

Secretarial issues must be dealt with via the medical secretariat during the week, or by email addressed to the patient's metabolic medicine specialist.

Certificate issued on

Dr